Survival of Colorectal cancer (CRC) patients is considerably stage-dependent; therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aimed to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. 127 patients (68 males and 59 females) entered this study before receiving chemotherapy or radiotherapy. A control group of 50 healthy age/sex matched individuals (27 males and 23 females) were included in the study. The serum levels of GM-CSF and IL-7 were measured using commercial enzyme linked immunosorbent assays. A significantly higher level of GM-CSF was found in the sera of patients with colorectal cancer compared to healthy age/sex matched controls (P=0.013). However, there was no significant difference between the levels of IL-7 in sera of patients and controls. We observed a significant elevation in the level of GM-CSF in poorly differentiated tumors (P=0.024). Also a significant correlation between lymphatic invasion and the level of GM-CSF in sera of CRC patients was detected (P=0.01).
nnually one million new cases of colorectal cancer (CRC) are diagnosed and half a million death occurs due to this cancer (1) . It represents the third and second most common cancer in men and women respectively, (10% and 9.4% of all cancers, respectively) but its mortality is less in women than in men. The survival rate of CRC is significantly different in early stages versus A Submmited 16 Oct 2013; Accepted 15 Dec 2013 Downloaded from ijmcmed.org at 11:02 +0430 on Saturday August 3rd 2019 late stages (1) . In fact, staging is the most important factor in evaluating the prognosis of colorectal cancer (2) ; therefore, early diagnosis and treatment can reduce mortality and morbidity of this cancer (1).
The immune system plays a dual role in the defence and development of many tumors.
Interestingly, tumor cells may exploit or produce effectors of the immune system for their own advantage. Colony Stimulating Factors (CSFs) are among the cytokines that are produced by cancer cells as well as the immune system in the course of tumorigenesis (3) . Cytokines can also modulate several processes involved in tumor progression and metastasis, for example angiogenesis and the production of metalloproteinases (4) .
Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF) is a cytokine that acts as a growth factor for white blood cells, and stimulates bone marrow to produce granulocytes and macrophages (5) . GM-CSF is highly efficient in inducing specific immune responses resulting in tumor destruction (6) . On the other hand, the production of GM-CSF correlates with the increase of recurrence rates in head and neck squamous cell carcinoma, possibly due to an inhibition of immune responsiveness (7) . GM-CSF exerts an important role in regulation of intestinal immune and inflammatory responses (8) . The establishment of normal colon epithelium is under the tight regulation of GM-CSF by controlling apoptosis and proliferation of these cells; therefore, GM-CSF deregulation is suggested to be a part of colon carcinogenesis. Moreover, GM-CSF can decrease apoptosis in colon cancer (9) and has a role in growth and cancer spreading (10) .
On the other hand, CRC cells with microinstability (MSI) gene can generate abnormal peptides that stimulate the secretion of cytokines (including GM-CSF), the infiltration of lymphocytes and stimulate the immune system against tumor, which can lead to a better prognosis for the patients (6) . An increase in the level of GM-CSF in sera of colorectal cancer patients was shown to correlate with tumor prognosis (5) .
Another cytokine which is shown to be produced by epithelial cells, keratinocytes, dendritic cells, hepatocytes, neurons, but not lymphocytes is Interleukin 7 (IL-7) (11) . The expression of functional IL-7 receptor (IL-7R) on epithelial tumor cells including a colon cancer cell line was reported (12) . IL-7 is a glycoprotein that is normally secreted by stromal cells in the red marrow and thymus and stimulates the proliferation of pre-B and pro-B cells while it supports the maturation of megakaryocytes and stimulates the proliferation of early and mature activated T-cells (13) . It is responsible of increasing the production of cytotoxic T cells and T killer cells and induces proinflammatory cytokine secretion and the anti-tumor activity of monocytes and T cells (14) . IL-7 also enhances the expression and in some patients (17) . Conversely, IL-7 is reported to be elevated in sera of patients with colorectal cancer at stages III and IV. This notion has resulted in considering IL-7 as a diagnostic or prognostic factor in this cancer (18) (19) (20) .
Increased GM-CSF mRNA, protein and its receptor have been found in many colon cancer cell lines, as well as in surgical specimens (21) (22) . GM-
CSF and Macrophage-Colony Stimulating Factor
(M-CSF) were reported to stimulate the metastatic properties of carcinoma cell lines and correlate with tumor prognosis (5, (23) (24) . There are few reports Downloaded from ijmcmed.org at 11:02 +0430 on Saturday August 3rd 2019 that have examined GM-CSF in the pathogenesis of colorectal cancer, and the studies on the level of IL-7 in these patients are scarcer.
In the present study we aimed to determine the pre-treatment serum levels of GM-CSF and IL-7 in 
Samples
Four ml blood was collected from peripheral veins of patients on the day before surgery. 
ELISA assays
The plasma level of GM-CSF was measured by a commercial enzyme linked immunosorbent assay (ELISA) (eBiosciences, Austria) according to the manufacturer's instructions. The sensitivity of this assay was 0.6 pg/ml and the range of detection was between 7.8-500 pg/ml. The serum level of IL-7 was measured using a commercial ELISA assay (Abcam, UK) according to the manufacturer's instructions. The sensitivity of this assay was less than 3 pg/ml and the range of detection was between 6.25-200 pg/ml.
Statistical analysis
Student's t-test was used for the analysis of age and gender distribution between the case and the control groups. One-way ANOVA or t-test was used for the comparisons between the two groups using SPSS software (11.5, Chicago, Illinois).
When the data points were less than 30 in categories, the normality of data was checked and parametric or non parametric (Kruskal-Wallis and Mann-Whitney) analyses were performed. Statistically significant differences were defined as comparisons resulting in p<0.05.
Results
A significantly higher level of GM-CSF (12.49±27.28 pg/ml) was found in the sera of patients with colorectal cancer compared with healthy age/sex matched controls (2.21 ± 15.68 pg/ml), (P= 0.013). Due to the high variance of data the analysis was performed by non-parametric comparison of the means (Mann-Whitney) and the results were confirmed (P=0.000). However, there There was no significant correlation between tumor type, tumor side, tumor size, perineural invasion, vascular invasion and lymph node involvement with either of GM-CSF or IL-7 cytokines levels.
Discussion
In this study we observed a significantly higher level of GM-CSF in Iranian patients with CRC compared to their age/sex matched controls.
Previous studies have shown that the increased level of local cytokines in the site of tumor stimulates the immune system against tumor and CSFs have the most important role in this event (3).
On the other hand, cytokines and growth factors produced by cancer cells or the stroma of tumor stimulate tumor growth and invasiveness (10) . The detection of CSF receptors in several solid tumor cells including CRC cells may contribute to the stimulation of tumor by these cytokines (9) . In a few investigations in other populations the level of GM-CSF in sera of CRC patients has been quite variable. One study has shown that elevated level of GM-CSF in sera of CRC patients does not correlate with prognosis or clinical features of CRC (5) . A study found no GM-CSF in sera of CRC patients (25) , while another group found a slight elevation of GM-CSF level in sera of CRC patients (26) . It is shown that CRC cells not only express GM-CSF receptor but also secrete GM-CSF thereby stimulating their own proliferation (3). The odd, however, is that combining GM-CSF with chemotherapy leads to better treatment of many solid tumors with a mild inhibition of angiogenesis or moderate apoptosis in CRC cells (27) (28) (29) .
Moreover, colon cancer cells genetically engineered
to secrete GM-CSF, have been shown to afford specific and long-lasting anti-tumor immunity (6) .
The exact explanation for the variable results on the production of GM-CSF in CRC and the mechanisms behind its dual (or multiple) role against tumor cells is not known. However, it has been suggested that a slight elevation in the serum GM-CSF levels may reflect a protective response in cancer patients, while higher levels of autologous GM-CSF may stimulate the metastatic properties of cancer cells (26) . Accordingly, the addition of recombinant GM-CSF at doses ranging between 30 pg/ml and 30 ng/ml did not appear to affect the Downloaded from ijmcmed.org at 11:02 +0430 on Saturday August 3rd 2019 poliferation of colorectal cancer cell lines in culture (22) .
A previous report showed that the level of IL- In one study, IL-7 was only detectable in higher stages of the tumor. In our hands, IL-7 was only produced by tumors in stage 3a where the production of GM-CSF decreased. On the contrary, there are other reports showing that IL-7 is increased in colorectal cancer and it can be used as a diagnostic or prognostic factor in this cancer (18) (19) (20) . Moreover, the transition from stage 3 to stage 4 of colorectal cancer is characterized by an increase of the serum level of IL-7 (18) (19) (20) .
The mean concentrations of both IL-7 and GM-CSF are reported to be high in females with colorectal cancer but did not reach the significant level (10). Mroczko et al. observed higher serum levels of IL-3, GM-CSF and M-CSF in males in comparison to females, but again, these differences were not significant (10) . Our results, however, did not show any difference between the levels of GM-CSF and IL-7 in male and female patients.
Currently it is difficult to interpret the discrepancy of the IL-7 data obtained in our study and some previous studies but as mentioned by others, what actually operate in vivo are the cytokine cascades and cytokine networks (26) . In addition, part of these differences may be due to the diversity of the cells of a specific tumor type in different patients. Moreover, as shown for breast tumor cells, even in the same host, tumor cells show transcriptional diversity (30) . Therefore, obtaining a consensus pattern of cytokine production by colorectal (and other) tumor cells in different individuals needs the evaluation of a broader range of cytokines in a greater number of patients.
We did not find any correlation between tumor type, tumor side, tumor size, perineural invasion, vascular invasion, and lymph node involvement with either GM-CSF or IL-7 cytokines. Similarly, another study reported no correlation between the serum levels of GM-CSF and the clinicopathological findings in colorectal cancer (26) . In summary, due to a high percentage of patients with elevated serum level of GM-CSF, we suggest that GM-CSF can be used as a tumor marker in Iranian colorectal cancer patients, however, the specificity and sensitivity of the test should be defined in future studies. We also suggest that the role of IL-7 in colorectal cancer needs more investigation and may provide a new target in the immunotherapy of colorectal cancer.
